LEVEMIR
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Oct 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
LEVEMIR by Novo Nordisk is insulin, including levemir, is regulation of glucose metabolism. Approved for glycemic control in adult. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEVEMIR (insulin detemir) is a long-acting basal insulin analog administered by subcutaneous injection, approved by FDA in October 2005. It is indicated for glycemic control in adults with diabetes mellitus. The drug works by stimulating peripheral glucose uptake in skeletal muscle and adipose tissue while inhibiting hepatic glucose production, lipolysis, and proteolysis. LEVEMIR serves as a foundational basal insulin therapy in the treatment landscape for both type 1 and type 2 diabetes.
$0.3BPart D
Mechanism of Action
insulin, including LEVEMIR, is regulation of glucose metabolism. Insulins and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances…
Indications (1)
Clinical Trials (20)
A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
Started Jun 2013
46 enrolled
DiabetesDiabetes Mellitus, Type 2
Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
Started May 2009
3,421 enrolled
DiabetesDiabetes Mellitus, Type 2
Levemir-Body Composition and Energy Metabolism
Started Mar 2009
42 enrolled
Type 2 Diabetes
Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®
Started Jan 2009
74 enrolled
DiabetesDiabetes Mellitus, Type 2
Observational Study on Levemir® in Obese Diabetic Patients
Started Dec 2008
580 enrolled
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Worked on LEVEMIR at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.